Effects of siRNAs on signalling rebound correlate well with sensitization in viability assays (Fig. 5g), as knockdown of either BRAF or CRAF, but not ARAF, sensitise KRAS-mutant NSCLC cells to MEKi although again not as strongly as SHOC2 knockdown. Here, KRAS is linked to non-small cell lung carcinoma.